MOSQUITO BORNE DISEASE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Global mosquito borne disease market size is expected to reach US$ 5.10 Bn by 2030, from US$ 3.11 Bn in 2023, exhibiting a CAGR of 7.3% during the forecast period.

Mosquito borne diseases are illnesses caused by parasites, viruses or bacteria that are transmitted to humans through the bite of an infected mosquito. These diseases include malaria, dengue fever, yellow fever, chikungunya, Zika virus, and others. The mosquito borne disease market is growing steadily due to rising incidence, increasing awareness, favorable government support and advanced treatments being developed. The key drivers are rising prevalence of mosquito borne diseases globally, growing initiatives by government and non-profit organizations, and ongoing R&D to develop effective therapies.

Global Mosquito Borne Disease Market- Regional Insights

• North America is expected to be the largest market for mosquito borne disease market during the forecast period, accounting for over 40.0% of the market share in 2023. The growth of the market in North America is attributed to high awareness, access to advanced treatments, presence of leading healthcare companies, and strong government support for elimination of mosquito borne diseases.
• Asia Pacific market is expected to be the second-largest market for mosquito borne disease market, accounting for over 31.1% of the market share in 2023. The growth of the market is attributed to high disease burden, tropical climate suiting mosquito growth, improving healthcare infrastructure and rising healthcare expenditure.
• Latin America market is expected to be the fastest-growing market for mosquito borne disease market, with a share of 19.2% during the forecast period. The growth of the market in Latin America is attributed to increasing incidence of mosquito borne diseases such as dengue, Zika and chikungunya in the region.

Analyst View: The global mosquito borne disease market is poised to grow substantially in the coming years. Several factors are driving the growth of this market such as growing prevalence of mosquito borne diseases like dengue, chikungunya, yellow fever, and Zika virus infections worldwide. Increase in global travel and trade along with rising urbanization and climate changes are facilitating the spread of mosquitoes to new regions, thereby accelerating the transmission of these diseases. The market will further receive a boost from increasing awareness about prevention and treatment of mosquito borne ailments. Heavy investments by public as well as private players to control mosquito populations and spread of related infections are also expected to propel the market.

Figure 1. Global Mosquito Borne Disease Market Share (%), By Region, 2023

To learn more about this report, request a free sample copy

Global Mosquito Borne Disease Market- Drivers

• Increasing prevalence of mosquito borne diseases: Rising prevalence of infectious diseases transmitted by mosquitoes such as malaria, dengue, chikungunya, Zika and yellow fever is a major factor driving the global mosquito borne disease market. According to WHO, there were 241 million cases of malaria worldwide in 2020. Mosquito-borne diseases accounted for 17% of all infectious diseases globally. The high morbidity and mortality caused by these diseases has increased efforts to control mosquito populations. Stone slabs help to reduce mosquito breeding sites, and are being widely adopted for lining drains, wells, water tanks, and others.This boosts demand for stone slabs optimized for mosquito control.
• Government initiatives for mosquito control: Government organizations are undertaking initiatives to drive mosquito-borne diseases by promoting the use of stone slabs. National and regional programs are distributing subsidized stone slabs to vulnerable communities. For Example, the Enhanced Dengue Control Program by the Philippine Department of Health distributes lava stone slabs prevents dengue outbreaks. Similarly, the Mangaluru City Corporation in India distributed subsidized stone slabs to place in overhead tanks to prevent mosquito breeding. Such initiatives are creating awareness and fueling the market growth.
• Cost-effectiveness of stone slabs: Mosquito repellent stone slabs are economical as compared to other mosquito control measures such as indoor spraying, mosquito nets, vaporizers, and others. Once installed, stone slabs provide long-term protection without any recurring costs. Their low maintenance makes them suitable for rural and low income areas. This cost-effectiveness boosts adoption among residential buildings, villages and municipalities with limited budgets. Heavy subsidies by governments also make these slabs affordable.
• Expanding applications of stone slabs: Stone slabs, previously limited to lining drains and tanks, are now being designed for diverse applications such as manhole covers, garden pathways, fence walls, cattle troughs, and others. Crafted stone slabs containing mosquito repellent additives are gaining popularity for these new applications. Their versatility makes them a convenient solution suitable for both interiors and exteriors across urban and rural settings. This is widening the scope and fueling market growth.

Global Mosquito Borne Disease Market- Opportunities

• Development of improved products: Manufacturers have immense scope for innovation in developing stone slabs with enhanced performance for mosquito control. Parameters such as active ingredient types and dosage, stone composition, durability, applicability and aesthetics can be improved for superior mosquito repulsion. R&D investments can help to discover novel materials and designs tailored to consumer requirements. This can help companies to differentiate through unique value propositions.
• Growing demand in developing regions: Developing countries in Asia Pacific, Latin America and Africa represent significant untapped market. These regions have favorable tropical climates, high prevalence of mosquito-borne diseases and lack awareness of effective solutions. Players can target these markets through educational marketing, highlighting stone slabs as a chemical-free and sustainable option. Tie-ups with local retailers and NGOs can aid the market penetration.
• Integration of new technologies: Companies can leverage technologies like nanotechnology, automation and IoT to enhance product features. For instance, RFID (Radio Frequency Identification) tags on slabs could provide data on performance metrics. Similarly, nanotech can develop slabs with improved durability, controlled release and uniform dispersion of active ingredients. Adoption of smart manufacturing can also optimize production. Such innovations can help gain competitive edge.
• Online sales platforms: The availability of stone slabs through e-commerce sites provides access to a wider consumer base, especially in urban areas. Users can view all product details online and have slabs delivered to their doorstep. Digital marketing on social media can also boost brand awareness. Investments into user-friendly e-commerce interfaces and partnerships with popular online retailers can support growth.

Global Mosquito Borne Disease Market- Trends

• Shift towards eco-friendly mosquito control solutions: Growing awareness about harmful effects of chemical pesticides has boosted demand for eco-friendly mosquito repellent solutions. Stone slabs present a chemical-free alternative that curb mosquito breeding without harming the environment. Their durability and low maintenance requirements makes them a sustainable option. These eco-friendly advantages boosts adoption of stone slabs for mosquito control.
• Use of natural ingredients and essential oils: Manufacturers are incorporating more plant- radio frequency identification based ingredients like citronella oil, lemongrass oil, eucalyptus oil, and others in stone slabs to avoid synthetic additives. Consumers are also demanding products made from natural raw materials like specific granite, marble or sedimentary rock varieties which have inherent mosquito repelling properties. These trends are in line with greater preference for natural solutions.

Global Mosquito Borne Disease Market- Restraints

• Lack of awareness in low income regions: There is lower awareness regarding mosquito repellent stone slabs in rural areas and urban slums where mosquito-borne disease burden is high. These consumers lack access to information on product availability which limits uptake of the market growth. Companies need to invest more in educational marketing in such regions to overcome this restraint.
• Minimal supporting infrastructure: The reach of stone slabs is constrained by lack of supporting infrastructure in many communities. Masonry skills required for customized slab installation may be inadequate. Distribution channels are still limited in remote areas. Lack of financing options also restricts affordability for lower income groups.
• Competition from alternative solutions: Mosquito repellent stone slabs compete with other established solutions like vaporizers, indoor sprays, nets and coils. Consumer familiarity and aggressive promotion of such existing products by large FMCG player’s poses a barrier for stone slab adoption. Winning consumer trust requires substantial marketing investments.

Figure 2. Global Mosquito Borne Disease Market Share (%), By Disease Type, 2023

To learn more about this report, request a free sample copy

Global Mosquito Borne Disease Market- Recent Developments

New Product Launches

• In September 2022, GSK, a pharmaceutical company, announced that the World Health Organization (WHO) had awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK’s groundbreaking malaria vaccine. This is the first prequalification for a malaria vaccine, It is a crucial stage in the vaccination program's introduction in nations where P. falciparum malaria transmission is moderate to high.
• In July 2022, GSK, a pharmaceutical company, announced that it had received approval for Mosquirix, the first malaria vaccine, by European Medicines Agency (EMA). Mosquirix acts against plasmodium falciparum malaria which is most prevalent in Africa. This vaccine has potential to save thousands of lives.
• In August 2021, The International Vaccine Institute (IVI), an independent, nonprofit, international organization, announced that the first participant received Bharat Biotech International Ltd’s (BBIL), a leading vaccines & bio-therapeutics manufacturers, Chikungunya vaccine candidate (BBV87) in a Phase II/III clinical trial in Costa Rica, marking the start of a multi-country study led by IVI in partnership with BBIL and funded by the Coalition for Epidemic Preparedness Innovations (CEPI) with support from the Ind-CEPI mission of the Department of Biotechnology, India
• In June 2021, Bharat Biotech, a leading vaccines & bio-therapeutics manufacturers, announced the launch of Chikungunya vaccine with brand name Chikungunya Vacc-DCV in India. This vaccine has potential to reduce chikungunya disease burden in India and globally.

Acquisition, Agreement, Partnerships and Research & Development Activities

• On October 11, 2023, UNICEF, United Nations International Children's Emergency Fund, announced an agreement with Serum Life Sciences for the year 2024 – 2028 for vaccine pre-qualification from the World Health Organization, to secure supply of the world’s second malaria vaccine, R21/Matrix-M. The deal is a major milestone towards meeting the high demand for doses of new vaccines against malaria – a disease which still kills one child under five every minute.
• In June 2022, GSK, a pharmaceutical company, acquired Affinivax Inc, a clinical stage biopharmaceutical company pioneering a novel vaccine technology platform. This US$ 2.1 billion acquisition enhanced GSK's vaccines research and development capabilities and pipeline for diseases like pneumonia.
• In December 2021, GSK, a pharmaceutical company, and Medicago, a biotechnology company, announced positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects (adults 18 years and above) across six countries
• In July 2020, GSK, a pharmaceutical company, and Medicago, a biotechnology company, announced a partnership to jointly develop plant-derived COVID-19 vaccines. Under this partnership, GSK provided adjuvant for Medicago's COVID-19 vaccine candidate, enhancing immunogenicity.

Top companies in Global Mosquito Borne Disease Market

• GlaxoSmithKline plc
• Sanofi S.A.
• Pfizer Inc.
• Merck & Co., Inc.
• Novartis AG
• Johnson & Johnson
• Eisai Co., Ltd
• Takeda Pharmaceutical Company Limited
• AstraZeneca
• Valeant Pharmaceuticals International, Inc.
• Mitsubishi Tanabe Pharma Corporation
• Abbott
• Hoffmann-La Roche Ltd
• Sun Pharmaceutical Industries Ltd
• Lupin Pharmaceuticals, Inc.
• BioCryst Pharmaceuticals, Inc.
• Mallinckrodt Pharmaceuticals
• Serum Institute of India Pvt. Ltd.
• CSL Limited
• Teva Pharmaceutical Industries Ltd

Definition: Global mosquito borne disease market refers to the drugs, vaccines, diagnostic tests and vector control methods used for the treatment, diagnosis and prevention of diseases transmitted by mosquitoes. These diseases include malaria, dengue, chikungunya, yellow fever, Zika virus, West Nile virus and other viral diseases spread through mosquito bites. The market comprises of pharmaceutical therapies, immunizations, insecticides, larvicides, mosquito nets and other personal protection tools that aid in controlling and eliminating mosquito-borne diseases that impact human health and burden healthcare systems globally each year. With rising incidence and increasing research, the mosquito borne disease market is witnessing steady growth.

Few Other Promising Reports In Pharmaceutical Industry

Infectious Disease Diagnostics Market

Dengue Vaccines Market

Malaria Diagnostics Market

Malaria Vaccines Market